WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca PLC Stock

$65.53-0.46 (-0.7%)
Updated Jan 27, 2023
AZN Price
$65.53
Fair Value Price
$67.42
Market Cap
$202.88B
52 Week Low
$52.65
52 Week High
$72.12
P/E
118.07x
P/B
5.77x
P/S
3.76x
PEG
1.07x
Dividend Yield
2.21%
Revenue
$45.15B
Earnings
$2.04B
Gross Margin
68.7%
Operating Margin
5.32%
Profit Margin
4.5%
Debt to Equity
1.68
Operating Cash Flow
$9B
Beta
0.55
Next Earnings
Feb 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AZN Overview

AstraZeneca PLC, is a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. Its offers products for oncology, cardiovascular, renal, and metabolism diseases, respiratory and immunology, rare diseases, respiratory syncytial virus, Influenza, schizophrenia bipolar disease, gastroenterology, and COVID-19. AstraZeneca was incorporated in 1992 and is headquartered in Cambridge, U.K.

Zen Score

Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AZN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AZN ($65.53) is undervalued by 2.8% relative to our estimate of its Fair Value price of $67.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AZN ($65.53) is not significantly undervalued (2.8%) relative to our estimate of its Fair Value price of $67.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AZN ($65.53) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AZN due diligence checks available for Premium users.

Be the first to know about important AZN news, forecast changes, insider trades & much more!

AZN News

Valuation

AZN fair value

Fair Value of AZN stock based on Discounted Cash Flow (DCF)
Price
$65.53
Fair Value
$67.42
Undervalued by
2.80%
AZN ($65.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AZN ($65.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AZN ($65.53) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AZN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
118.07x
Industry
30.12x
Market
23.59x
AZN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AZN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

AZN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.77x
Industry
5.24x
AZN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AZN price to earnings growth (PEG)

For valuing profitable companies with growth potential
AZN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

AZN's financial health

Profit margin

Revenue
$11.0B
Net Income
$1.6B
Profit Margin
14.9%
AZN's Earnings (EBIT) of $2.40B... subscribe to Premium to read more.
Interest Coverage Financials
AZN's profit margin (4.5%) has... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$94.2B
Liabilities
$59.0B
Debt to equity
1.68
AZN's short-term liabilities ($24.85B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AZN's long-term liabilities ($34.18B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AZN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.9B
Investing
-$1.7B
Financing
-$1.4B
AZN's operating cash flow ($8.83B)... subscribe to Premium to read more.
Debt Coverage Financials

AZN vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
AZN$202.88B-0.70%118.07x5.77x
NVS$193.92B-0.39%9.14x3.19x
PFE$245.81B-1.04%8.25x2.65x
BMY$154.04B-0.74%23.45x4.71x
ABBV$258.69B-0.76%19.43x16.17x

Astrazeneca Stock FAQ

What is Astrazeneca's quote symbol?

NASDAQ: AZN) Astrazeneca trades on the NASDAQ under the ticker symbol AZN. Astrazeneca stock quotes can also be displayed as NASDAQ: AZN.

If you're new to stock investing, here's how to buy Astrazeneca stock.

What is the 52 week high and low for Astrazeneca (NASDAQ: AZN)?

(NASDAQ: AZN) Astrazeneca's 52-week high was $72.12, and its 52-week low was $52.65. It is currently -9.14% from its 52-week high and 24.46% from its 52-week low.

How much is Astrazeneca stock worth today?

(NASDAQ: AZN) Astrazeneca currently has 1,548,000,000 outstanding shares. With Astrazeneca stock trading at $65.53 per share, the total value of Astrazeneca stock (market capitalization) is $202.88B.

Astrazeneca stock was originally listed at a price of $18.00 in Dec 31, 1997. If you had invested in Astrazeneca stock at $18.00, your return over the last 25 years would have been 264.06%, for an annualized return of 5.3% (not including any dividends or dividend reinvestments).

How much is Astrazeneca's stock price per share?

(NASDAQ: AZN) Astrazeneca stock price per share is $65.53 today (as of Jan 27, 2023).

What is Astrazeneca's Market Cap?

(NASDAQ: AZN) Astrazeneca's market cap is $202.88B, as of Jan 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Astrazeneca's market cap is calculated by multiplying AZN's current stock price of $65.53 by AZN's total outstanding shares of 1,548,000,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.